Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40097 | 0.85 | L3MBTL1 (0.59) | L3MBTL1KDM4EMAOBAOC3KMT2A | |
| SCHEMBL3070962 | 0.84 | L3MBTL1 (0.57) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL30167649 | 0.82 | L3MBTL1 (0.55) | L3MBTL1KDM4EMAOBAOC3KMT2A | |
| SCHEMBL7199868 | 0.82 | L3MBTL1 (0.56) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL2550199 | 0.82 | KDM4E (0.63) | L3MBTL1KDM4EMAOBAOC3KMT2A | |
| SCHEMBL9215275 | 0.81 | L3MBTL1 (0.55) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL3923640 | 0.81 | MAPT (0.50) | L3MBTL1KDM4EKMT2ALMNAHSD17B10 | |
| SCHEMBL8764656 | 0.81 | L3MBTL1 (0.54) | L3MBTL1KDM4EMAOBAOC3KMT2A | |
| SCHEMBL2093115 | 0.81 | KDM4E (0.58) | L3MBTL1KDM4EMAOBAOC3KMT2A | |
| SCHEMBL10043036 | 0.81 | L3MBTL1 (0.54) | L3MBTL1KDM4EMAOBAOC3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4157834-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | Mission Therapeutics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| EP-4126852-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021239863-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021191390-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| EP-3728192-A1 | NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| EP-3681864-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019053634-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2019-03-21 | — | — | WO | disclosed |
| EP-3060549-B1 | NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE | DAE WOONG PHARMA (KR) | 2019-02-13 | — | — | EP | disclosed |
| WO-2015060613-A1 | NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-04-30 | — | — | WO | disclosed |
| EP-2744805-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | Amgen Inc. (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013149376-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013122897-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013025883-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2010056195-A1 | NEW COMPOUNDS 575 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| EP-1940799-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007047676-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |